IMAB vs. INCR, RGLS, CRVO, IXHL, ACET, RPTX, DMAC, PRLD, PDSB, and SGMT
Should you be buying I-Mab stock or one of its competitors? The main competitors of I-Mab include InterCure (INCR), Regulus Therapeutics (RGLS), CervoMed (CRVO), Incannex Healthcare (IXHL), Adicet Bio (ACET), Repare Therapeutics (RPTX), DiaMedica Therapeutics (DMAC), Prelude Therapeutics (PRLD), PDS Biotechnology (PDSB), and Sagimet Biosciences (SGMT). These companies are all part of the "pharmaceutical preparations" industry.
I-Mab (NASDAQ:IMAB) and InterCure (NASDAQ:INCR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.
In the previous week, I-Mab and I-Mab both had 2 articles in the media. I-Mab's average media sentiment score of 1.43 equaled InterCure'saverage media sentiment score.
I-Mab presently has a consensus price target of $12.25, indicating a potential upside of 588.20%. Given I-Mab's higher possible upside, research analysts clearly believe I-Mab is more favorable than InterCure.
InterCure has higher revenue and earnings than I-Mab.
38.4% of I-Mab shares are owned by institutional investors. Comparatively, 8.3% of InterCure shares are owned by institutional investors. 22.1% of I-Mab shares are owned by insiders. Comparatively, 0.2% of InterCure shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
I-Mab has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500. Comparatively, InterCure has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500.
I-Mab received 53 more outperform votes than InterCure when rated by MarketBeat users. However, 100.00% of users gave InterCure an outperform vote while only 62.92% of users gave I-Mab an outperform vote.
Summary
I-Mab beats InterCure on 6 of the 10 factors compared between the two stocks.
Get I-Mab News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
